Display options
Share it on

Rare Tumors. 2015 May 18;7(2):5765. doi: 10.4081/rt.2015.5765. eCollection 2015 May 05.

Breast Metastasis from Medullary Thyroid Carcinoma in a Male Patient: Case Report and Review of the Literature.

Rare tumors

Stylianos Mandanas, Efterpi Margaritidou, Varvara Christoforidou, Eleni Karoglou, Chrysoula Geranou, Alexandra Chrisoulidou, Maria Boudina, Konstantinos Georgopoulos, Kalliopi Pazaitou-Panayiotou

Affiliations

  1. Department of Endocrinology, Theagenio Cancer Hospital , Thessaloniki, Greece.
  2. Department of Pathology, Theagenio Cancer Hospital , Thessaloniki, Greece.
  3. Department of Radiology, Theagenio Cancer Hospital , Thessaloniki, Greece.

PMID: 26266011 PMCID: PMC4508642 DOI: 10.4081/rt.2015.5765

Abstract

Medullary thyroid carcinoma (MTC) is a rare malignancy that may metastasize to liver, lungs and bones. Breast is an unusual metastatic site for MTC and only 20 female cases have been reported in the literature. We present a male patient in whom histological examination and immunohistochemistry of a breast mass were indicative of breast metastasis from MTC. A 67-year-old man with recent diagnosis of MTC and metastases to cervical and upper mediastinum lymph nodes was referred to our department for further treatment. At first evaluation, diagnostic imaging techniques showed lung and bone metastases and three months later the presence of liver metastases. Due to the extension of the disease, treatment with vandetanib was decided, but serious adverse events led to its interruption after two weeks. During follow-up, patient developed a painful swelling in the right breast. Ultrasound and mammography showed the presence of multiple masses to the right breast suspicious for malignancy. Core needle biopsy and histological examination of the specimen confirmed the presence of metastatic MTC. Palliative external beam irradiation was used to relieve local pain and, after one month, the patient died. Consequently, breast masses should be cautiously evaluated, mainly in the presence of a known primary malignancy. Histological and/or cytopathological examination are requisite diagnostic tools, while external beam irradiation and tyrosine kinase inhibitors may be used as palliative therapies in the concurrent presence of breast metastases from MTC.

Keywords: Medullary thyroid cancer; breast metastasis; tyrosine kinase inhibitor

References

  1. Endocrine. 2013 Aug;44(1):264-5 - PubMed
  2. Ann Diagn Pathol. 2008 Feb;12 (1):67-71 - PubMed
  3. Thyroid. 2010 Jul;20(7):831-2 - PubMed
  4. Ann Clin Lab Sci. 1994 Sep-Oct;24(5):441-7 - PubMed
  5. Postgrad Med J. 1995 Dec;71(842):744-5 - PubMed
  6. Cytopathology. 2009 Dec;20(6):403-5 - PubMed
  7. Breast J. 2004 Mar-Apr;10 (2):162 - PubMed
  8. Thyroid. 2009 Feb;19(2):197-9 - PubMed
  9. AJR Am J Roentgenol. 1995 Jul;165(1):65-6 - PubMed
  10. Clin Nucl Med. 2010 Jul;35(7):512-3 - PubMed
  11. World J Surg Oncol. 2007 Jul 05;5:74 - PubMed
  12. J Clin Oncol. 2012 Jan 10;30(2):134-41 - PubMed
  13. Am Surg. 2004 Apr;70(4):287-90 - PubMed
  14. Thyroid. 2009 Jun;19(6):565-612 - PubMed
  15. Diagn Cytopathol. 2012 Apr;40(4):297-304 - PubMed
  16. Acta Cytol. 1998 Mar-Apr;42(2):446-8 - PubMed
  17. Exp Clin Endocrinol. 1991;98(1):37-41 - PubMed
  18. Diagn Cytopathol. 1988;4(3):254-7 - PubMed

Publication Types